Skip to main content

Table 4 Summary of Survival Data for Effective Agents in the Tsc2-/- Subcutaneous Tumor Model

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

Reference Start Criteria Treatment Cohort Dosing Median Survival
(days)
Percent Difference From Untreated Drug class
Current Study Tumor Volume of 100 mm3 Untreated - 31 -  
   Rapamycin 8 mg/kg 3 days/wk 84.5 173% *
   Asparaginase 2IU/g twice/wk × 4 wks 39.5 27% #
   Asparaginase + Rapamycin 2IU/g twice/wk × 4 wks + 8 mg/kg 3 days/wk 71 129%  
   Sunitinib 80 mg/kg 5 days/wk 39 26% #
   Sunitinib + Rapamycin 80 mg/kg 5 days/wk + 8 mg/kg 3 days/wk 80 158%  
   Bevacizumab 5 mg/kg once/2 wks 38.5 24% #
   Bevacizumab + Rapamycin 5 mg/kg once/2 wks + 8 mg/kg 3 days/wk 60 94%  
Lee et al, 2009 Tumor Volume of 150 mm3 Untreated - 24.5 -  
   Rapamycin 8 mg/kg 5 days/wk 46 88% *
   Sorafenib 60 mg/kg 5 days/wk 19.5 -20%  
   Sorafenib + Rapamycin 60 mg/kg 5 days/wk + 8 mg/kg 5 days/wk 53 116% **
Messina et al, 2007 Tumor Volume of 50 mm3 for early treatments, 250 mm3 for late treatments Untreated - 31 -  
   Early CCI-779 8 mg/kg 5 days/wk 47 52% *
   Early Rapamycin 8 mg/kg 5 days/wk 62 100% *
   Late Rapamycin 8 mg/kg 5 days/wk 59 90% *
Lee et al, 2006 Tumor Volume of 300 mm3 Untreated - 17.5 -  
   CCI-779 8 mg/kg 5 days/wk 41 134% *
   IFN-γ 20,000 units 3 days/wk 22 26% #
   IFN-γ + CCI-779 20,000 units 3 days/wk + 8 mg/kg 5 days/wk 56 220% **
Lee et al, 2005 18 Days after injection with Tsc2-/- cells Untreated - 33 -  
   CCI-779 4 mg/kg 3 days/wk 69 109% *
   IFN-γ 20,000 units 3 days/wk 50 52% #
  1. * Single agent mTOR inhibitor (all agents and doses were more effective than no treatment)
  2. ** Combination containing mTOR inhibitor that was more effective than single agent mTOR inhibitor
  3. # Single agent other than mTOR inhibitor that was more effective than no treatment